News
Jan 13, 2025
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
Read MoreSep 4, 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs through Clinical Development
Read MoreMay 6, 2024
ArsenalBio Announces Presentation of Four Abstracts at ASGCT Annual Meeting Highlighting New Mechanisms for Leveraging CAR T Cells to Address Solid Tumor Cancers
Read MoreApr 30, 2024
Arsenal Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of AB-2100 in Development as a Treatment for Clear-cell Renal Cell Carcinoma
Read MoreApr 5, 2024
Arsenal Biosciences Announces Presentation of Four Abstracts at AACR Annual Meeting Highlighting New CAR T-Focused Research
Read MoreJan 2, 2024